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Clinical management for uterine 
sarcomas 
F. Amant, A. Coosemans, M. Debiec-Rychter, D. Timmerman, I. Vergote
Malignant pure mesenchymal uterine tumours encompass endometrial stromal sarco-
ma (ESS), uterine leiomyosarcoma (ULMS) and undifferentiated sarcomas. ESS refers 
to low-grade ESS and is distinctive from undifferentiated uterine sarcomas. For both 
entities, there are no pathognomonic features on any imaging technique. In early stage 
disease and both for ESS and ULMS, hysterectomy with bilateral salpingo-oöphorec-
tomy but without lymphadenectomy is the standard surgical treatment. The clinical 
benefit of chemotherapy is limited and this underscores the importance of targeted 
therapy. ESS and ULMS are driven by different pathways resulting in a different clinical 
behaviour. ESS is typically a hormone sensitive tumour with an indolent growth. ULMS 
is notorious for its aggressive growth and poor outcome. Individualisation of treatment 
is mandatory since randomised trials are nearly non-existing. The progesterone and 
oestrogen receptor are clinically important targets for most primarily advanced or re-
current ESS and a subset of recurrent ULMS.
(Belg J Med Oncol 2010;4:196-2)
Practice guidelines
Introduction
Mesenchymal tumours, other than uterine 
fibroids, are uncommon since sarcomas of the 
uterus comprise only 3% of uterine malignancies.¹ 
Uterine sarcomas encompass leiomyosarcoma 
(ULMS), carcinosarcoma and endometrial stromal 
sarcoma (ESS) according to traditional classification 
systems. The focus in this contribution will be on 
the most common pure mesenchymal tumours: 
ULMS and ESS. ESS was formerly classified as low-
grade ESS. Tumours that used to be termed high-
grade ESS are currently called poorly differentiated 
or undifferentiated uterine sarcoma. Although there 
is no universal staging system for uterine sarcomas, 
the FIGO surgical staging system for endometrial 
cancer is used.
No imaging modality can offer a reliable preoperative 
diagnosis. Computed tomography (CT) is unable 
to differentiate between different types of uterine 
pathology. Ultrasonography and magnetic resonance 
imaging (MRI) offer a much more detailed analysis 
of pathology. However, while several features at 
ultrasonography and MRI may raise suspicion of 
a uterine sarcoma, there are no pathognomonic 
features on any imaging technique. Hysterectomy is 
advocated when imaging modalities cannot exclude 
a malignancy. 
The purpose of this manuscript is to present the 
current standard treatment of ULMS and ESS. 
Only few series are reported and results from 
Authors: F. Amant, MD, PhD1; A. Coosemans MD1; M. Debiec-Rychter2, MD, PhD; D. Timmerman, MD, PhD1; I. Vergote MD, PhD1; 1Leuven 
Cancer Institute (LKI), Gynaecological Oncology and 2 Department of Human Genetics; University Hospital Gasthuisberg, Catholic University 
of Leuven, Leuven, Belgium
 Please send all correspondence to: F. Amant, MD, PhD; Leuven Cancer Institute, Gynaecological Oncology, University Hospital 
Gasthuisberg,Catholic University Leuven, Belgium; Tel: +32-16-34 42 52; Fax: +32-16-34 46 29; E-mail: Frederic.amant@uz.kuleuven.ac.be
Conflict of interest: the authors have nothing to disclose and indicate no potential conflicts of interest.
Key words: : uterine, leiomyosarcoma, endometrial, stromal, targeted, biology, hormonal
Belgian Journal of Medical Oncology	 	 	 volume	4,	issue	5,	2010
197
level 1 evidence studies are non-existing. Knowledge 
of tumour biology forms the basis to delineate 
targeted treatment modalities. This contribution is 
a summary of a recently published review.2
Uterine leiomyosarcome (ULMS)
Most ULMSs are sufficiently differentiated, at least 
focally, to permit recognition of their smooth muscle 
nature. They are obviously malignant on microscopic 
examination. The diagnostic strategy should include 
a search for the mitotic index, presence of atypia and 
coagulative tumour cell necrosis.3  ULMSs needs to 
be distinguished from mitotically active or atypical 
leiomyomas and uterine smooth muscle neoplasms 
with low malignant potential. Coagulative tumour 
cell necrosis is decisive and should be distinguished 
from hyaline and ulcerative necrosis.3 
Current treatment of ULMS
Adnexal or lymphatic spread is only present in 
approximately 3% of early stage ULMS.4,5 Lymph 
node involvement is more frequent in advanced stage 
disease. In a series of 1,396 patients, adnexectomy 
and lymphadenectomy failed to be independent 
prognostic factors on survival.6 The ovaries are 
however frequently removed because of the age, 
small chance of ovarian metastasis and the potential 
for a low-grade hormone sensitive ULMS. A simple 
hysterectomy with oophorectomy but without 
lymphadenectomy is therefore standard treatment 
for early stage ULMS (Figure 1). In premenopausal 
women, a simple hysterectomy may be considered.7 
There is no proven benefit for any adjuvant 
treatment. Only two randomized trials explored 
the benefit of adjuvant treatment.8,9 The value of 
adjuvant doxorubicin was already investigated 
almost 20 years ago. Randomising 156 women 
with resected stage I-II sarcoma including various 
histologies (ULMS, carcinosarcoma and ESS) 
and non-random use of adjuvant pelvic radiation, 
survival rates were comparable for doxorubicin or 
control group.8 This single randomized trial on 
adjuvant chemotherapy contained only 48 ULMS. 
Recurrences occurred in 11/25 (44%) and 14/23 
(61%) cases in the doxorubicin and control arm, 
respectively. Although this study is considered 
negative, the results are in fact inconclusive. 
Reed et al. randomized 103 ULMS to either 
observation or pelvic radiation, 51 Gy in 28 fractions 
over 5 weeks. There was no benefit for patients with 
ULMS receiving adjuvant radiotherapy.9
In advanced stage or recurrent disease treatment is 
palliative only.7 Quality of life should be considered 
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Figure 1. Treatment strategy for early stage endometrial stromal sarcoma  and uterine leiomyosarcoma.
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at every stage. ULMS with transperitoneal spread is 
more difficult to resect when compared to ovarian 
cancer. This is mainly explained by a more infiltrative 
growth. As a result, cytoreductive surgery without 
residual tumour is less likely to be achieved. Systemic 
treatment is the best option when the aim is to prolong 
life. Single agent treatment has the least toxicity 
and is favoured. Response rates of single agent and 
combination chemotherapy are summarised in Table 
1. Combinations that are not mentioned are too toxic 
or showed less activity. Doxorubicin still shows the 
best balance between activity and toxicity and is a first 
line option with a response rate of 25%. Gemcitabine 
is active in combination with docetaxel10 but has 
also activity as a single agent drug.11 A prospective 
randomized phase II study has shown that gemcitabine-
docetaxel is superior to gemcitabine alone for soft 
tissue sarcoma in terms of response rate, progression-
free survival and overall survival.12 However, response 
rates were low (16% and 8%) and more toxicity was 
noted in the combination arm. Most patients received 
prior cytotoxic therapy in this series. In a previously 
unexposed series of ULMS, post resection gemcitabine-
docetaxel yielded a 2-year progression free survival 
of 39 months.13 This combination deserves to be 
further investigated in ULMS. Trabectedin (formerly 
known as ecteinascidin-743 or ET-743) is a novel 
tetrahydroisoquinoline isolated from a marine tunicate 
is a promising drug but the reported activity refers to a 
pooled analysis with low numbers.
ULMS showing a disease-free interval exceeding 
6 months or more deserve a different approach.14 
Disease free interval is an indicator of tumour 
biology and these ULMS might have a less 
aggressive growth pattern. This subset of ULMS 
is more likely to express hormonal receptors that 
allow targeted treatment (see below). Hormonal 
treatment or surgery may  first be considered instead 
of chemotherapy. Resection of a solitary metastasis 
may improve the outcome.14 Since most ULMS 
portend an aggressive growth, resection of isolated 
metastases will benefit only a highly selected group.
Targeted treatment in ULMS
Targets to the ER and PR successfully have 
been used in the subset of ULMS with indolent 
growth. Case reports show responses to 
medroxyprogesteroneacetate, aromatase inhibitor 
or mifepristone (an antiprogestin also designated 
RU-486) (Table 2). Aromatase inhibitors block 
the conversion of androgens to oestrogens in 
peripheral fat tissue. The antiprogestational activity 
of mifepristone (RU-486) results from a competitive 
interaction with progesterone at the PR. Ideally, 
the receptor status is determined in the recurrent 
tumour. The results from a running clinical phase 
II trial (NCT00414076), comparing the use of 
letrozole vs. expectative management in ULMS are 
eagerly awaited.  The efficacity of mifepristone (RU-
486) and ICI 182,780 (a pure oestrogen antagonist 
Table 1. Single agent and combination chemotherapy activity in uterine leiomyosarcomas as 
reported in the literature.2
Series Drug Schedule Response RR 
n (%)
Omura (1983) Doxorubicin 60 mg/m², 3w 7/28 (25)
Sutton (1992) Ifosfamide 1.5 mg/m², 5d 6 PR 6/35 (17)
Sutton (1999) Paclitaxel 175 mg/m², 3w 3 CR 3/33 (9)
Gallup (2003) Paclitaxel 175 mg/m², 3w 4 CR 4/48 (8)
Look (2004) Gemcitabine 1000 mg/m², 1-8-15 1 CR, 8 PR 9/42 (20)
Anderson (2005) Temozolomide 50-75 mg/m², 6-8w 1CR 1/13 (8)
Sutton (2005) Liposomal doxorubicin 50 mg/m², 4w 1 CR, 4 PR 5/35 (16)
Amant (2009) ET-743 1.5 mg/m², 3w 5 PR 5/11 (45)
Hensley (2002)
‘single institution’ 
Gemcitabine
Docetaxel
900 mg/m², d1&8
100 mg/m², d8
3 CR, 15 PR
18/34 (53)
Hensley (2008)
‘collaborative study’ 
Gemcitabine
Docetaxel
900 mg/m², d1&8
100 mg/m², d8
3 CR, 10 PR
13/48 (27)
PR: partial remission; CR: complete remission; N: number of patients
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also called fulvestrant) deserves further study. 
Clinically applicable approaches to counteract the 
effects of PTEN loss in ULMS include PI3K, AKT 
and mTOR inhibitors.
Endometrial stromal sarcoma (ESS) 
Endometrial stromal neoplasms are exclusively 
composed of cells resembling the endometrial 
stroma in its proliferative phase. The stromal nodule 
is the benign variant; it has well circumscribed 
borders and is rare.  Endometrial stromal sarcoma 
(ESS) represents the entity with infiltrating 
borders and behaves like a low-grade sarcoma, 
with the potential for recurrence and metastasis.15 
Microscopic findings that unequivocally 
correspond to ESS include a uniform population 
of endometrial stromal-type cells invading the 
myometrium and myometrial vessels. Historically, 
ESSs were subdivided into low-grade and high-
grade tumours. However, high-grade tumours 
lack the typical growth pattern and vascularity of 
low-grade ESS and show destructive myometrial 
invasion rather than the lymphatic permeation of a 
low-grade ESS. Moreover, they demonstrate marked 
cellular pleomorphism and brisk mitotic activity. 
As a result, ESS is now considered best restricted 
to malignancies that were formally referred to as 
low-grade ESS. In this chapter we only discuss the 
ESS according to the new definition (i.e. former low-
grade ESS).
Endometrial sarcomas without recognisable 
evidence of a definite endometrial stromal 
phenotype, designated as poorly differentiated 
endometrial sarcomas, are almost invariably 
high grade,16 and termed poorly differentiated or 
undifferentiated uterine sarcoma. These high grade 
tumours show similarity with ULMS when the 
clinical presentation, imaging studies, treatment 
modalities and prognosis are considered.
Current treatment of ESS
Preoperative imaging is mandatory since ESS tends 
to spread to the lungs and peritoneum.15 Most ESSs 
(65-86%) will present with disease limited to the 
uterus (stage I-II disease).15,17 Hysterectomy is the 
cornerstone of the treatment in early stage disease 
(Figure 1). The peritoneal cavity should be explored 
simultaneously.
Lymphatic involvement by ESS is well established, 
as evidenced by a prior pathologic designation of 
endolymphatic stromal myosis. Although nodal 
involvement increases the stage, lymphadenectomy 
in all ESS is unlikely to improve the survival.17-19 A 
policy of leaving nodes behind in a small series did 
not result in isolated retroperitoneal recurrences that 
might hamper the prognosis.18 In a large population-
based analysis including 831 women with all grades 
ESS, nodal involvement of grade 1 and 2 ESS 
(probably similar to low-grade ESS) was 6.0% and 
8.9%, respectively.19 However, lymphadenectomy had 
no demonstrable effect on survival.19 In another series 
including 384 ESS, nodal involvement was detected in 
7/100 (7%) women undergoing lymphadenectomy.19 
However, also in this large series, no survival benefit 
was noted for women undergoing lymphadenectomy.19 
This observation may be explained by the high (86 vs. 
95% for node positive vs. negative cases in the Shah 
series, respectively) 5-year survival of node positive 
ESS.19 The smaller than expected impact of nodal 
metastasis is also explained by the tendency of ESS 
to recur transperitoneally or in the lungs.15  It appears 
from these data that systematic lymphadenectomy 
for ESS is not indicated. When lymph nodes are 
pathologically enlarged, lymphadenectomy is 
considered part of a cytoreductive procedure. The 
controversy on this topic is at least partially fed by the 
inclusion of both low- and high grade sarcomas in the 
studies.17 Chan et al. observe a poorer survival in node 
positive cases. However, the high grade sarcomas 
count in large part for this outcome. Also, incidences 
of nodal involvement need to be interpreted with the 
status of other extra-uterine locations. Lymph node 
involvement in tumours with other gross extrauterine 
involvement is unlikely to be prognostic. 
Standard treatment for ESS is hysterectomy 
with bilateral salpingo-oophorectomy. Although 
surgical castration is a logic intervention for a 
hormone sensitive disease, the clinical benefit 
remains unproven. Therefore, in young women this 
policy deserves a critical analysis. It appears from 
small18,20-22 and large17,19 non-randomized series 
that leaving the ovaries in situ does not worsen the 
outcome. Management of menopausal symptoms 
may be challenging in young women. Oestrogen 
replacement therapy in women with a history of ESS 
was associated with a poor outcome.20 These data 
were however based on 5 women only and need 
Practice guidelines
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to be confirmed. In young women we advocate a 
thorough discussion on the risk and benefit of 
surgical castration. Individualisation of the surgical 
approach in this group of patients is important. 
After providing this information, we would accept 
to treat small ESS (< 2-3 cm) in a woman younger 
than 35 years of age without surgical castration.
Since ESS express both the ER and PR, adjuvant 
targeted hormonal treatment can be considered 
to reduce recurrence rates.18,20 Progestins or 
aromatase inhibitors may be considered. There 
are no prospective studies investigating adjuvant 
treatment for ESS. Even retrospective data on 
clinical benefit are limited. Apart from this, there 
are no valid data on the duration of treatment and 
it is unknown whether the menopausal status (e.g. 
after oophorectomy) affects any treatment induced 
effect. The benefit of adjuvant medroxyprogesterone 
acetate 250mg or megestrol acetate 160mg on a 
daily basis during 2 years has been suggested in 
two small studies.18,20 Side effects of progestins 
include thrombosis and weight gain (higher 
circulating oestrogen levels), whereas aromatase 
inhibitors are associated with osteoporosis and 
muscle/joint complaints. The history and condition 
of the patient may help deciding on the treatment of 
choice, if necessary.
For ESS with primarily transperitoneal spread, 
cytoreductive surgery is advocated because of the 
low grade nature of the disease and the efficacy 
of hormone receptor targeted treatment.23  Organ 
resection (splenectomy, partial bowel resection) 
can be considered, especially if this contributes 
to the absence of residual tumour.23 The decision 
to resect distant metastasis (frequently lung 
parenchym) should be taken on an individual 
basis. Adjuvant hormonal  treatment  is advocated 
until progression.
ESS has an indolent growth with a tendency for 
late recurrence. Recurrences are common, even 
in early stage disease. Relapse occurs in 36-
56% of early stage disease.15,24 The median time 
to recurrence was 65 and 9 months for stages 
1 and 3-4, respectively.15 The indolent growth 
makes aggressive and repeated surgery valuable. 
Secondary and tertiary cytoreductive procedures 
with or without resection of distant metastases 
(e.g. lung parenchyma, cardiac) should be con-
sidered.23,25 Intervals between the surgeries can 
be extended by targeting the hormone receptors 
(Figure 1).24
When the hormonal armamentarium is exhausted, 
in the absence of hormonal receptors or when 
progression into a high grade malignancy occurs,25 
ifosfamide and doxorubicin appear to be active 
cytotoxic drugs.26 
Targeted treatment for ESS
The PR is the most important target for hormonal 
treatment. Experience is mainly available with progestins 
(medroxyprogesteron acetate, megestrolacetaat, 
17-alpha hydroxyprogesterone caproate). At least 
25 cases have been reported in 16 studies, with a 
response rate of 76% (19/25). Aromatase inhibitors 
reduce oestrogen levels by inhibiting oestrogen 
synthesis in both tumour tissue and peripheral sites 
and as a consequence they inhibit the proliferation of 
the tumour. Letrozole was most frequently used and 
response rate was induced in 8/9 (88%) cases. Injection 
of GnRH analogues resulted in partial remission in a 
single case. The efficacity of mifepristone (RU-486) and 
ICI 182,780 (fulvestrant) deserves further study.  
Table 2. Successful targeted treatment in uterine leiomyosarcoma.2
Author N Target Hormone Clinical 
response
Response
duration 
Uchida (1996) 1 Progesterone 
receptor
medroxyprogesteroneacetate PR 3 ¾ years
Hardman (2007) 1 Estrogen receptor anastrazole PR 1 year
Koivisto-Korander (2007) 1/3$ Progesterone 
receptor
mifepristone PR 3 years
O’Cearbhaill (2009) 34 Oestrogen 
receptor
Aromatase inhibitor
(74% letrozole)
9% PR 5 months
N: number of patients; PR: partial remission; $: 1 out of 3 patients
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Other uterine sarcomas
Undifferentiated sarcoma
Undifferentiated uterine sarcoma is a poorly defined 
group. They do not show evidence of gene-specific 
fusions, suggesting that these tumours arise by 
a different pathogenetic mechanism than ESS. 
Immunohistochemical data are also sparse, including 
only a few cases per article published.
Gastrointestinal stromal tumours 
Gastrointestinal stromal tumours (GISTs) are 
the most common mesenchymal tumours of the 
gastrointestinal tract (GI). Rare cases are identified 
outside the GI tract and are collectively known as 
extragastrointestinal stromal tumours (EGISTs). 
EGISTs that present as gynaecologic masses are 
rare but may be more common than is currently 
recognized.27-29  
Primary activating mutations in the KIT or PDGFRA 
genes, which result in constitutive activation of 
receptor tyrosine kinase activity, are early oncogenic 
events in majority of adult GISTs. However, a subset 
of tumors (10-15%) show a wild-type KIT and 
PDGFRA genotype. Immunohistochemical staining 
for KIT (CD117) has become integral to the diagnosis 
of GISTs, nearly 95% of which is positive for this 
marker. Establishing the diagnosis of KIT-negative 
GIST remains a challenge and is best handled by a 
reference pathologist with expertise in this area. The 
use of mutational analysis of the kinase genes KIT 
and PDGFRA is the standard of care in such cases.
Imatinib mesylate provides targeted therapy for 
GIST by inhibiting the KIT and PDGFRA tyrosine 
kinases. Clinical benefit is achieved in approximately 
85% of patients with unresectable or metastatic 
disease, with a median progression-free survival 
of 20 to 24 months. Importantly, the tumour KIT/
PDGFRA kinase genotype has predictive significance 
with regard to the response to imatinib therapy; the 
presence of a KIT juxtamembrane mutation being 
the single best predictor of response to imatinib. 
Therefore, mutational analysis before imatinib 
treatment for unresectable or metastatic disease is 
strongly recommended. 
Conclusion
Uterine sarcomas are uncommon and the diagnosis 
is preoperatively frequently unknown. As a result, 
centralisation, large series and randomised trials 
are problematic. Hysterectomy is the cornerstone 
of the treatment for early stage ULMS and ESS. 
There is no proven benefit from any adjuvant 
treatment (radiotherapy, chemotherapy, hormonal 
targeted) for both entities. Hormone receptors are 
the most important targets for primarily advanced 
or recurrent ESS, as for a subset of recurrent 
ULMS. Progestins and aromatase inhibitors show 
the highest clinical activity. The efficacity of new 
targeted drugs for uterine sarcomas is still explored. 
Centralisation and intergroup studies are the only 
appropriate answer to the current lack of evidence.
Key messages for clinical practice
1. Uterine sarcomas are uncommon and randomized studies are hardly available. 
The evidence is mostly based on retrospective (small) series.
2. Hysterectomy with bilateral salpingo-oophorectomy is the surgical treatment for 
early stage uterine leiomyosarcoma. For advanced stage and recurrent disease, 
chemotherapy may prolong life. A subset has an indolent growth rendering sur-
gery and hormone therapy beneficial.
3. Hysterectomy with bilateral salpingo-oophorectomy is the surgical treatment for 
early stage endometrial stromal sarcoma. For young women, surgical castration 
can be avoided. Given the low grade tumor, cytoreductive surgery followed by 
hormonal treatment is adviced for advanced stage and recurrent disease.
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